Treatment of Candidiasis
For invasive candidiasis and candidemia, echinocandins are the first-line treatment; for oral candidiasis, use topical clotrimazole or nystatin for mild disease and oral fluconazole for moderate-to-severe disease; for vulvovaginal candidiasis, use either topical azoles or a single 150-mg dose of oral fluconazole; and for esophageal candidiasis, use oral fluconazole 200-400 mg daily. 1, 2
Invasive Candidiasis and Candidemia
Echinocandins remain the cornerstone of therapy for candidemia and invasive candidiasis, with the 2025 global guideline reinforcing this recommendation while adding rezafungin as a new once-weekly option 1. The specific dosing includes:
- Caspofungin: 70 mg loading dose, then 50 mg daily
- Micafungin: 100 mg daily
- Anidulafungin: 200 mg loading dose, then 100 mg daily
- Rezafungin: Once-weekly dosing (new agent) 1
Alternative agents include liposomal amphotericin B (3-5 mg/kg daily) combined with flucytosine in certain situations, or fluconazole (400-800 mg daily) for susceptible isolates after clinical stability 2.
Critical management steps:
- Remove central venous catheters whenever feasible 2
- Perform dilated retinal examination to rule out endophthalmitis 2
- Continue therapy for 2 weeks after documented clearance from bloodstream and resolution of symptoms 2
- Consider earlier IV-to-oral step-down in stable non-neutropenic patients 1
Important caveat: Echinocandins should NOT be used for CNS or ocular infections due to poor penetration; use liposomal amphotericin B with or without flucytosine for these sites 1, 2.
Oropharyngeal Candidiasis
Mild disease:
- Clotrimazole troches 10 mg 5 times daily for 7-14 days, OR
- Nystatin suspension 4-6 mL (100,000 U/mL) 4 times daily for 7-14 days 2
Moderate-to-severe disease:
- Oral fluconazole 100-200 mg daily for 7-14 days 2
Fluconazole-refractory disease:
- Itraconazole solution 200 mg once daily, OR
- Posaconazole suspension 400 mg twice daily for 3 days, then 400 mg daily 2
- Alternative: IV echinocandin or amphotericin B deoxycholate 2
Vulvovaginal Candidiasis
Uncomplicated VVC (90% of cases):
- Topical azoles (any formulation—no single agent superior), OR
- Oral fluconazole 150 mg single dose 2
Recent 2025 network meta-analysis data suggests single-dose oral fluconazole has marginally higher early clinical cure rates compared to multiple-day topical therapy (OR 1.52), though both are highly effective 3.
Severe acute VVC:
- Fluconazole 150 mg every 72 hours for 2-3 total doses 2
C. glabrata VVC (azole-resistant):
- Boric acid 600 mg intravaginal gelatin capsule daily for 14 days, OR
- Nystatin suppositories 100,000 units daily for 14 days 2
- Oteseconazole is now available as a novel oral option for resistant infections 1, 4
Recurrent VVC:
- 10-14 days induction therapy (topical or oral fluconazole)
- Followed by fluconazole 150 mg weekly for 6 months 2
Esophageal Candidiasis
Fluconazole-susceptible organisms:
- Oral fluconazole 200-400 mg (3-6 mg/kg) daily for 14-21 days 2
Fluconazole-refractory disease:
- Itraconazole solution 200 mg daily, OR
- Voriconazole 200 mg twice daily, OR
- IV echinocandin (same dosing as candidemia), OR
- Amphotericin B deoxycholate 0.3-0.6 mg/kg daily 2
Urinary Tract Candidiasis
Cystitis (fluconazole-susceptible):
- Oral fluconazole 200 mg (3 mg/kg) daily for 2 weeks
- Remove indwelling bladder catheter if present 2
Cystitis (C. glabrata or C. krusei):
- Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days, OR
- Oral flucytosine 25 mg/kg 4 times daily for 7-10 days 2
- Consider amphotericin B bladder irrigation (50 mg/L sterile water daily for 5 days) 2
Pyelonephritis:
- Fluconazole 200-400 mg daily for 2 weeks (if susceptible)
- Eliminate urinary obstruction; remove/replace nephrostomy tubes or stents 2
Special Considerations
Emerging resistance concerns: The 2025 guideline emphasizes managing Candidozyma auris (formerly C. auris) and azole-resistant C. parapsilosis with susceptibility-guided therapy and infection control measures 1, 5. Prior antifungal exposure increases risk of non-albicans species 6.
Neonatal candidiasis: Use amphotericin B deoxycholate 1 mg/kg IV daily or liposomal amphotericin B 5 mg/kg daily; fluconazole 12 mg/kg daily for step-down therapy. Always perform lumbar puncture and dilated retinal exam 2.
Respiratory tract isolation: Candida from respiratory secretions usually represents colonization and rarely requires treatment 2.
Common pitfall: Unnecessary treatment of candiduria—31.3% of patients in one real-world cohort received antifungal therapy without clear indication 6. Asymptomatic candiduria in non-neutropenic patients without urologic procedures typically does not require treatment.